PMID- 25495002
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20221207
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 20
IP  - 10 Suppl
DP  - 2014 Oct
TI  - Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus.
PG  - S204-15
AB  - OBJECTIVES: To compare 1-year clinical outcomes and cost efficiency of treating 
      adults with type 2 diabetes mellitus (T2DM) with canagliflozin (300 mg/day) or 
      sitagliptin (100 mg/day), both added on a background of metformin and 
      sulfonylurea. STUDY DESIGN: An economic model integrated data from an 
      active-controlled, randomized trial, claims database analyses, and published 
      literature. METHODS: The model adopted a US managed care payer perspective and 
      included the clinical and economic impact of achieving specific clinical quality 
      goals. The model was run separately for 2 single clinical quality metrics, 
      glycated hemoglobin (A1C) < 7% (used as base case) or < 8%, and 4 composite 
      metrics (A1C < 7% or < 8% combined with body mass index < 30 kg/m2 and blood 
      pressure < 140/90 mm Hg or low-density lipoprotein cholesterol < 100 mg/dL). Cost 
      savings of achieving versus not achieving metrics were derived from a claims 
      database analysis. Drug and adverse event costs were included. RESULTS: In the 
      base case, compared with sitagliptin 100 mg, treatment with canagliflozin 300 mg 
      resulted in $215 in annual cost savings and 12.3 absolute percentage points more 
      patients achieving goal. Similar findings were found across all other quality 
      metrics (difference in proportion achieving goal ranging from 6.7% to 19.0% and 
      annual savings ranging from $1 to $669). Canagliflozin remained cost saving 
      versus sitagliptin in sensitivity analyses. CONCLUSIONS: Canagliflozin 300 mg may 
      represent a cost-efficient T2DM treatment option versus sitagliptin 100 mg for 
      patients on metformin plus sulfonylurea due to lower overall costs and better 
      achievement of A1C and quality composite goals.
FAU - Ektare, Varun U
AU  - Ektare VU
FAU - Lopez, Janice M S
AU  - Lopez JM
FAU - Martin, Silas C
AU  - Martin SC
FAU - Patel, Dipen A
AU  - Patel DA
FAU - Rupnow, Marcia F T
AU  - Rupnow MF
FAU - Botteman, Marc F
AU  - Botteman MF
AD  - 4350 E W Highway, Ste 430, Bethesda, MD 20814. E-mail: mbotteman@pharmerit .com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
MH  - Adult
MH  - Canagliflozin/adverse effects/economics/*therapeutic use
MH  - Cost Savings
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy/economics
MH  - Drug Costs
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Health Care Costs
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/economics/*therapeutic use
MH  - Male
MH  - Models, Economic
MH  - Sitagliptin Phosphate/adverse effects/economics/*therapeutic use
MH  - Treatment Outcome
EDAT- 2014/12/17 06:00
MHDA- 2016/10/07 06:00
CRDT- 2014/12/16 06:00
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
AID - 85778 [pii]
PST - ppublish
SO  - Am J Manag Care. 2014 Oct;20(10 Suppl):S204-15.